Sean E. Browne - 18 Oct 2022 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Role
President and CEO, Director
Signature
/s/ Amy Culbert, attorney-in-fact
Issuer symbol
XTNT
Transactions as of
18 Oct 2022
Net transactions value
-$85,828
Form type
4
Filing time
20 Oct 2022, 16:19:49 UTC
Previous filing
18 Oct 2021
Next filing
17 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XTNT Common Stock, $0.000001 par value Sale $54,008 -80,000 -4.9% $0.6751 1,557,684 18 Oct 2022 Direct F1, F2, F3
transaction XTNT Common Stock, $0.000001 par value Sale $31,820 -51,100 -3.3% $0.6227 1,506,584 19 Oct 2022 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6461 to $0.79, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 Includes 131,618 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 734,430 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6017 to $0.6433, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.